Publications

The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease.
Rambam Maimonides J Med
July 30, 2015

By applying the approach of the Framingham Heart Study to address CKD risk factors, we hope to mirror the success of cardiology; we aim to prevent progression to ESRD and to avoid the cardiovascular complications associated with CKD. In this paper, we present conceptual examples of risk factor modification for CKD, in the setting of this historical framework.

Association of APOL1 Genotype with Renal Histology among Black HIV-Positive Patients Undergoing Kidney Biopsy
Clin J of the Am Soc Nephol
December 14, 2015

APOL1 genotype may provide additional diagnostic information to traditional clinical variables in predicting underlying FSGS spectrum lesions in blacks who are HIV positive.

Invited Editorial: Hemostatic Factors, APOL1, and ESKD Risk— Another Piece of the Puzzle?
Clin J Am Soc Nephrol
April 17, 2015

APOL1 Nephropathy: From Gene to Mechanisms of Kidney Injury.
Nephrology Dialysis Transplantation
January 5, 2015

The contribution of African ancestry to the risk of focal segmental glomerulosclerosis and chronic kidney disease has been partially explained by the recently described chromosome 22q variants in the gene apolipoprotein L1 (APOL1). The APOL1 variants appear at a high allele frequency in populations of West African ancestry as a result of apparent adaptive selection of the heterozygous state. Heterozygosity protects from infection with Trypanosoma brucei rhodesiense. This review will describe the role of the approaches in population genetics for the description of APOL1-associated nephropathies and draw inferences as to the biologic mechanisms from genetic epidemiology findings to date. Modifier loci can influence APOL1 risk for the development of kidney disease. ‘Second hits’, both viral and non-viral, may explain the discrepancy between the remarkably high odds ratios and the low lifetime risks of kidney disease

COMPLETE LIST OF PUBLICATIONS

  1. Wasser WG, Tessler S, Kamath CP, and Sackin AJ. Nonfatal Amniotic Fluid Embolism: A Case Report of Post-Partum Respiratory Distress with Histopathologic Studies. Mount Sinai Journal of Medicine 46: 388-391, 1979
  1. Wasser WG, Bochman RS, Alderete M, and Alter AA. Immunoblastic Lymphadenopathy and Hypercalcemia. Mount Sinai Journal of Medicine 47: 13-16, 1980.
  1. Wasser WG, Krakoff LR, Haimov M, Glabman S and Mitty EA. Restoration of Renal Function Following Bilateral Renal Artery Occlusion. Archives of Internal Medicine 141: 1647-1651, 1981.
  1. Wasser WG, Goldstein MH, Barba. F and Churg J. Persistent Renal Failure Following Administration of Naproxen. Mount Sinai Journal of Medicine 49: 127-129, 1982.
  1. Wasser WG, Bronheim EE, Richardson BK. Theophylline Madness. Annals of Internal Medicine 95: 191, 1981.
  1. Wasser WG, Grishman E, Goldstein MD, Gerber M. Recurrent Nephropathy Associated with Heroin Use. Mount Sinai Journal of Medicine 52: 275, 1985.
  1. Wasser W, Feldman NS, D’Agati V. Chronic Renal Failure After Ingestion of Over- the- Counter Chromium Picolinate (Letter to the Editor). Annals of Internal Medicine 126: 410, 1997.
  1. Wasser WG, Yusuf SA, D’Agati VD. Over- the Counter Chromium and Renal Failure (Response to Letter to the Editor). Annals of Internal Medicine 127: 656, 1997.
  1. Wasser WG, Rossi CA, Glass GE, Hantavirus Antibodies in New York. (Letter to the Editor). Annals of Internal Medicine 127: 166-167, 1997.
  1. Musher DR, Wasser WG, Saggi SJ. High Dose Lamivudine and Hepatitis B. (Letter to the Editor). American Journal of Gastroenterology, 94: 3372, 1999.
  1. Charney DA, Wasser W. A 36-year old man with a monoclonal gammopathy and nephrotic syndrome. Amer J Kidney Diseases 42: 1097-1101, 2003.
  1. Behar DM, Rosset S, Tzur S, Selig S, Yudkovsky G, Bercovici S, Kopp JB, Winkler CA, Nelson GW, Wasser WG, Skorecki K. African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans. Human Molecular Genetics, 19: 1816-1827,2010
  1. Shlush LI, Bercovici S, Wasser WG, Yudkovsky G, Templeton A, Geiger D, Skorecki K. Admixture Mapping of End Stage Kidney Disease Susceptibility Using Estimated Mutual Information Ancestry Informative Markers BMC Medical Genomics 3:47, 2010
  1. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, Wasser WG, Behar D, Skorecki K. Missense mutations in the APOL1 gene are highly associated with end-stage kidney disease risk previously attributed to the MYH9 Human Genetics 128:345, 2010.

This article was judged to be one of 10 most clinically important nephrology studies published in 2011 by the American College of Physicians (Arora N, Chertow G.M. Update in Nephrology: Evidence Published in 2010. Ann Intern Med 154:1-5, 2011).

  1. Rosset S, Tzur S, Behar DM, Wasser WG, Skorecki K. The Population Genetics of Chronic Kidney Disease: Insights from the MYH9-APOL1 Nature Reviews Nephrology 7: 313,2011.

This paper was favorably reviewed by f1000 on 18 August 2011.

  1. Behar DM, Kedem E, Rosset S, Haileselassie Y, Tzur S, Kra-Oz Z, Wasser WG, Shenhar Y, Shahar E, Hassoun G, Maor C, Wolday D, Pollack S, Skorecki K. Absence of APOL1 Risk Variants Protects against HIV Associated Nephropathy in the Ethiopian Population. Amer J Nephrol 34(5):391-490,2011.
  1. Fine DM, Wasser WG,  Estrella MM, Atta MG, Kuperman M, Shemer R, Rajasekaran A,  Tzur S, Racusen, LC, Skorecki K. APOL1 Risk Variants Predict Histopathology and Progression to End-Stage in Patients with HIV-Related Kidney Disease J Amer Soc Nephrol 2011;34(5):452-9.
  1. Tzur S, Rosset S, Skorecki K, Wasser WG. APOL1 Allelic Variants are associated with Lower Age of Dialysis Initiation, and thereby Increased Dialysis Vintage in African and Hispanic Americans with Non-diabetic End-Stage Kidney Disease. Nephrology, Dialysis and Transplantation 2012 Apr;27(4):1498-505.
  1. Wasser WG, . Tzur S, Wolday D, Adu D, Baumstein D, Rosset S, Skorecki K. Population Genetics of Chronic Kidney Diseases: The Evolving Story of APOL1. J Nephrol 2012: 25 (5):603-18.
  1. Tzur S, Wasser WG, Rosset S, Skorecki K. Linkage Disequilibrium Analysis Reveals an Albuminuria Risk Haplotype Containing Three Missense Mutations in the Cubilin Gene with Striking Differences Among European and African Ancestry. BMC Nephrology 2012: 13:142.
  1. Skorecki K, Wasser WG. Hypertension Misattributed Kidney Disease in African Americans (Commentary for “APOL1 variants associate with hypertension-attributed nephropathy and rate of kidney function decline in African-American Study of Kidney Disease and Hypertension”). Kidney Int 2012; 83: 6-9.
  1. Ulasi II, Tzur S, Wasser WG, Shemer R, Kruzel E, Feigin E, Ijoma CK, Onodugo OD, Okoye JU, Arodiwe EB, Ifebunandu NA, Chukwuka CJ, Onyedum CC, Ijoma UN, Nna E, Onuigbo M,  Rosset S, Skorecki High Population Frequencies of APOL1 Risk Variants are Associated with Increased Prevalence of Hypertensive, Non-Diabetic Chronic Kidney Disease in the Igbo People from South-eastern, Nigeria. Nephron Clin Pract. 2013 Jul 13;123(1-2):123-128.
  1. Kruzel E, Wasser WG, Aviram S, Skorecki K. APOL1 Nephropathy: From Gene to Mechanisms of Kidney Injury. Nephrology Dialysis Transplantation 2015 Jan 5. pii: gfu391.
  1. Osafo C, Raji RY, Burke D, et al. Human Heredity and Health (H3) in Africa (H3A) Kidney Research Network: A Focus on Methods in Sub-Saharan Africa. Clin J Am Soc Nephrol epublished on July 2, 2015 as doi:10.2215/CJN.11951214.
  1. Wasser WG, Kruzel-Davila Invited Editorial: Hemostatic Factors, APOL1, and ESKD Risk— Another Piece of the Puzzle? Clin J Am Soc Nephrol 2015; 10:723-5.
  1. Wasser WG, Gil A, Skorecki K. The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease. Rambam Maimonides J Med, Jul 30;6(3). doi: 10.5041/RMMJ.10214.
  1. Atta M, Estrella, N, Skorecki K, Koop J, Winkler C, Wasser WG, et al. Association ofAPOL1 Genotype with Renal Histology among Black HIV-Positive Patients Undergoing Kidney  Clin J of the Am Soc Nephol 2015 Dec 14. pii: CJN.07490715.
  1. Feldman L, Vinker S, Efrati S, Beberashvilli I, Gorelik O, Wasser WG, Shani M. Amlodipine Treatment for Hypertension Associates with Decreased Dementia Risk. (submitted October, 2015).
  1. Izhakian , Wasser, WG, Fox BD, Vainshelboim B., Fuks L, Fruchter O. Kramer M. Lobar Distribution in Non-Cystic Fibrosis Bronchiectasis Predicts Bacteriologic Pathogen Treatment (submitted October, 2015).
  1. Abdel-Rahman N, Izhakian S, Wasser W, Fruchter O, Kramer Endobronchial Enigma:A Clinically Rare Presentation of Nocardiosis in an Immunocompetent Patient. Case Reports in Pulmonology (accepted December 2015)
  1. Izhakian , Wasser WG, Fox BD BM, Vainshelboim B, Kramer MR. The Diagnostic Value of the Pleural Fluid C-Reactive Protein Level in Parapneumonic Effusions: A Retrospective Cohort Study. BMC Pulmonary (submitted December 2015).
  1. Izhakian S, Wasser WG, Fox BD, Fruchter O, Vainshelboim B, Kramer MR Effect of Jewish and Arab Ancestry and Gender Matching on Clinical Outcome of Lung Transplant Patients in Israel (submitted, December 2015)

BOOK CHAPTERS:

  1. Skorecki K, Wasser WG. Hypertension Misattributed Kidney Disease in African Americans in Onuigbo, M: ACE Inhibitors in Medicine: Uses, Mechanisms of Action, and Potential Adverse Effects. Hauppauge, New York: Nova Science Publishers, 2013.
  1. Weir MR, Hanes DS, Klassen DK, Wasser WG. Antihypertensive Drugs, chapter 50 in Brenner and Rector’s The Kidney 10th Edition, 2015
  1. Hao C-M, Hou F-F, Wasser WG. The Far East, chapter 81 in Brenner and Rector’s The Kidney 10th Edition, 2015

ONLINE LISTS OF PUBLICATIONS

  1. PubMed
  2. ResearchGate

Comments are closed